Notizie AIOM – anno XV
Update to ASCO Clinical Practice Guideline on Potentially Curable Pancreatic Cancer
April 19, 2017 - An ASCO clinical practice guideline update, reported by Khorana et al in the Journal of Clinical Oncology, includes the recommendation of gemcitabine-capecitabine doublet therapy as an adjuvant therapy option in potentially curable pancreatic cancer. The ...Leggi tutto
Concept paper MABS2
Il Sole 24ore Sanità ha pubblicato il numero monografico dedicato alle "Opportunità e sfide dei biotecnologici e dei biosimilari nelle patologie linfoproliferative e reumatologiche. Integrare le variabili regolatorie, gli aspetti clinici e la sostenibilità ...Leggi tutto
Web-app
Una nuova web-app gratuita, in otto lingue, per computer, tablet e smartphone sul tumore dello stomaco è disponibile sul sito del Corriere della Sera in collaborazione con l'Associazione Italiana di Oncologia Medica (leggi e scarica). Strumento interattivo in due ...Leggi tutto
Annual Report to the Nation: Cancer Death Rates Continue to Decline
April 4, 2017 - Overall cancer death rates continue to decrease in men, women, and children for all major racial and ethnic groups, according to the latest Annual Report to the Nation on the Status of Cancer, 1975–2014, published by Jemal et al in the Journal of the ...Leggi tutto
ASCO Says Administrative Burdens Divert Time, Resources From Patients
April 12, 2017 - If your oncology practice is suffering from the rising costs of equipment and facilities, staffing costs are going up, and administration expenses are through the roof, you're not alone. More than half (54%) of practices are struggling with these pressures, ...Leggi tutto
The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting
Despite the availability of effective antiemetics and evidence-based guidelines, up to 40% of cancer patients receiving chemotherapy fail to achieve complete nausea and vomiting control. In addition to type of chemotherapy, several patient-related risk factors for chemotherapy-induced ...Leggi tutto
Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast CancerThe Randomized Clinical FinXX Trial
Capecitabine is not considered a standard agent in the adjuvant treatment of early breast cancer. The results of this study suggest that addition of adjuvant capecitabine to a regimen that contains docetaxel, epirubicin, and cyclophosphamide improves survival outcomes of ...Leggi tutto